The proposed Phase 1 clinical study of LUCID-21-302 (Lucid-MS) by the Company has received a No Objection Letter (“NOL”) from Health Canada, according to FSD Pharma Inc. A unique therapeutic candidate for the treatment of multiple sclerosis is being developed by FSD Pharma, a biopharmaceutical firm committed to developing a portfolio of cutting-edge assets and […]